Article Data

  • Views 284
  • Dowloads 126

Original Research

Open Access

Perivascular epithelioid cell tumor (PEComa) of gynecologic origin: a clinicopathological study of three cases

  • H.Y. Ye1,*,
  • J.G. Chen1
  • D.L. Luo2
  • Z.M. Jiang1
  • Z.H. Chen3

1Department of Gynecology and Obstetrics, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China

2Department of Pathology, Guangzhou, China

3Medical research Center, Guangdong General Hospital, Guangzhou, China

DOI: 10.12892/ejgo201201105 Vol.33,Issue 1,January 2012 pp.105-108

Published: 10 January 2012

*Corresponding Author(s): H.Y. Ye E-mail:


Perivascular epithelioid cell tumors (PEComas), occasionally associated with the tuberous sclerosis complex, are characterized by varying amounts of spindle and epithelioid cells with clear to eosinophilic cytoplasm that display immunoreactivity for melanocytic markers, most frequently HMB-45. Perivascular epithelioid cell tumor of gynecologic origin is very rare, and there have been only a few reported cases. This study describes the clinical, histological, and immunohistochemical features and prognoses of three cases of gynecologic origin. Two of the three tumors were confined to the uterus and one to the vagina. None of the patients had tuberous sclerosis complex. Immunohistochemistry indicated that all three cases expressed at least one melanocytic marker, and HMB45 was a positive marker for all of them. These markers can be found in both epithelial cells and spindle cells. Except for MiTF, which was located in the nucleus, all the other antibodies were located in the cytoplasm. The three cases have been followed up for 26, 22, and three months, respectively, with disease-free survival in all cases. We conclude that PEComas of gynecologic origin have morphological and immunohistochemical features of the PEComa family, which are rare and should be included in the differential diagnosis with other tumors. Until more cases of this rare tumor are evaluated with longer follow-up, firm criteria for malignancy remain uncertain.


PEComa; Perivascular epithelioid cell tumors; Gynecologic origin

Cite and Share

H.Y. Ye,J.G. Chen,D.L. Luo,Z.M. Jiang,Z.H. Chen. Perivascular epithelioid cell tumor (PEComa) of gynecologic origin: a clinicopathological study of three cases. European Journal of Gynaecological Oncology. 2012. 33(1);105-108.


[1] Bonetti F., Pea M., Martignoni G., Zamboni G.: “PEC and sugar”. Am. J. Surg. Pathol., 1992, 16, 307.

[2] Folpe A.L., Mentzel T., Lehr H.A., Fisher C., Balzer B.L., Weiss S.W.: “Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature”. Am. J. Surg. Pathol., 2005, 29, 1558.

[3] Azad N.S., Aziz A.B., Pervez S., Kayani N.: “Uterine perivascular epithelioid cell tumour presenting as a cervical mass”. J. Pak Med. Assoc., 2006, 56, 83

[4] Kalyanasundaram K., Parameswaran A., Mani R.: “Perivascular epithelioid tumor of urinary bladder and vagina”. Ann. Diagn. Pathol., 2005, 9, 275.

[5] Chen I.Y., Yang S.F., Chen F.M., Chai CY.: “Abdominopelvic perivascular epithelioid cell tumor with overt malignancy: a case report”. Kaohsiung J. Med. Sci., 2005, 21, 277.

[6] Fink D., Marsden D.E., Edwards L., Camaris C., Hacker N.F.: “Malignant perivascular epithelioid cell tumor (PEComa) arising in the broad ligament”. Int. J. Gynecol. Cancer, 2004, 14, 1036.

[7] Fukunaga M.: “Perivascular epithelioid cell tumor of the uterus: report of four cases”. Int. J. Gynecol. Pathol., 2005, 24, 341.

[8] Fadare O., Parkash V., Yilmaz Y., Mariappan M.R., Ma L., Hileeto D. et al.: “Perivascular epithelioid cell tumor (PEComa) of the uterine cervix associated with intraabdominal “PEComatosis: A clinicopathological study with comparative genomic hybridization analysis”. World J. Surg. Oncol., 2004, 2, 35.

[9] Hornick J.L., Fletcher C.D.: “PEComa: what do we know so far?”. Histopathology, 2006, 48, 75.

[10] Fadare O.: “Perivascular epithelioid cell tumor (PEComa) of the uterus: an outcome-based clinicopathologic analysis of 41 reported cases”. Adv. Anat. Pathol., 2008, 15, 63.

[11] Bonetti F., Pea M., Martignoni G., Zamboni G., Luzzolino P.: “Cellular heterogeneity in lymphangiomyomatosis of the lung”. Hum. Pathol., 1991, 22, 727.

[12] Gaffey M.J., Mills S.E., Zarbo R.J., Weiss L.M., Gown A.M.: “Clear cell tumor of the lung. Immunohistochemical and ultrastructural evidence of melanogenesis”. Am. J. Surg. Pathol., 1991, 15, 644.

[13] Gal A.A., Koss M.N., Hochholzer L., Chejfec G.: “An immunohistochemical study of benign clear cell (‘sugar’) tumor of the lung”. Arch. Pathol. Lab. Med., 1991, 115, 1034.

[14] Pea M., Bonetti F., Zamboni G., Martignoni G., Fiore-Donati L., Doglioni C.: “Clear cell tumor and angiomyolipoma”. Am. J. Surg. Pathol., 1991, 15, 199.

[15] Weeks D.A., Malott R.L., Arnesen M., Zuppan C., Aitken D., Mierau G.: “Hepatic angiomyolipoma with striated granules and positivity with melanoma-specific antibody (HMB-45): a report of two cases”. Ultrastruct. Pathol., 1991, 15, 563.

[16] Pan C.C., Jong Y.J., Chai C.Y., Huang S.H., Chen Y.J.: “Comparative genomic hybridization study of perivascular epithelioid cell tumor: molecular genetic evidence of perivascular epithelioid cell tumor as a distinctive neoplasm”. Hum. Pathol., 2006, 37, 606.

[17] Martignoni G., Pea M., Reghellin D., Zamboni G., Bonetti F.: “PEComas: the past, the present and the future”. Virchows Arch., 2008, 452, 119.

[18] Armah H.B., Parwani A.V.: “Perivascular epithelioid cell tumor”. Arch. Pathol. Lab. Med., 2009, 133, 648.

[19] Greene L.A., Mount S.L., Schned A.R., Cooper K.: “Recurrent perivascular epithelioid cell tumor of the uterus (PEComa): an immunohistochemical study and review of the literature”. Gynecol. Oncol., 2003, 90, 677.

[20] Jeon I.S., Lee S.M.: “Multimodal treatment using surgery, radiotherapy, and chemotherapy in a patient with a perivascular epithelioid cell tumor of the uterus”. J. Pediatr. Hematol. Oncol., 2005, 27, 681.

[21] Pea M., Bonetti F., Zamboni G., Martignoni G., Riva M., Colombari R. et al.: “Melanocyte-marker-HMB-45 is regularly expressed in angiomyolipoma of the kidney”. Pathology, 1991, 23, 185.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time